COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH PSORIATIC ARTHRITIS (PSA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN EUROPE

被引：0
|
作者：
Narayanan, S. [1 ]
Lu, Y. [2 ]
Hutchings, R. [2 ]
Baynton, E. [2 ]
机构：
[1] Ipsos Healthcare, Columbia, MD USA
[2] Ipsos Healthcare, London, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2574
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS4
引用
收藏
页码：A373 / A373
页数：1
相关论文
共 50 条
  • [21] DRUG SURVIVAL ON FIRST TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: COMPARISON ACROSS ETANERCEPT, ADALIMUMAB, GOLIMUMAB AND INFLIXIMAB
    Garcia-Porrua, C.
    Maceiras-Pan, F.
    Fernandez-Dominguez, L.
    Mosquera-Martinez, J. A.
    Correa-Rey, B.
    Pombo-Suarez, M.
    Pinto-Tasende, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1031 - 1031
  • [22] Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
    Wcislo-Dziadecka, Dominika
    Grabarek, Benjamin
    Swinarew, Andrzej S.
    Rozwadowska, Beata
    Zmarzly, Nikola
    Gola, Joanna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (02): : 262 - 268
  • [23] Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
    Chastek, Benjamin
    Fox, Kathleen M.
    Watson, Crystal
    Gandra, Shravanthi R.
    ADVANCES IN THERAPY, 2012, 29 (08) : 691 - 697
  • [24] COST PER RESPONDER OF APREMILAST VERSUS ETANERCEPT AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Tencer, T.
    Clancy, Z.
    Zhang, F.
    VALUE IN HEALTH, 2014, 17 (07) : A376 - A376
  • [25] Alopecia areata in a patient with psoriatic arthritis and Crohn's disease receiving etanercept
    Costa, Luisa
    Atteno, Mariangela
    Caso, Francesco
    Scarpato, Luigi
    Del Puente, Antonio
    Scarpa, Raffaele
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2014, 17 (02) : 219 - 220
  • [26] US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab.
    Zhang, Frank
    Li, Stan
    Curtis, Jeffrey R.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S946 - S946
  • [27] Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
    Benjamin Chastek
    Kathleen M. Fox
    Crystal Watson
    Shravanthi R. Gandra
    Advances in Therapy, 2012, 29 : 691 - 697
  • [28] Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab
    Behrens, Frank
    Koehm, Michaela
    Schwaneck, Eva C.
    Schmalzing, Marc
    Gnann, Holger
    Greger, Gerd
    Tony, Hans-Peter
    Burkhardt, Harald
    RHEUMATOLOGY, 2018, 57 (11) : 1938 - 1946
  • [29] Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
    Strand, Vibeke
    Mease, Philip J.
    Maksabedian Hernandez, Ervant J.
    Stolshek, Bradley S.
    Liu, Lyrica X. H.
    Collier, David H.
    Kricorian, Gregory
    Merola, Joseph F.
    RMD OPEN, 2021, 7 (01):
  • [30] Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
    Behrens, Frank
    Koehm, Michaela
    Schwaneck, Eva Christina
    Schmalzing, Marc
    Gnann, Holger
    Greger, Gerd
    Tony, Hans-Peter
    Burkhardt, Harald
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345